ABSTRACT
The advent of MRI has significantly advanced our understanding of the pathophysiology of multiple sclerosis, becoming an important endpoint in phase II and III clinical trials of disease-modifying therapies and hematopoietic stem cell transplantation. MRI is currently the best surrogate marker of subclinical disease activity and response to therapy in clinical practice.. Most importantly, MRI has become a key component of the MS diagnostic criteria, allowing early diagnosis and increased confidence in the diagnostic accuracy. Consensus-based MS specific imaging guidelines provide information to aid clinicians in the decision-making process regarding diagnosis, management, and detection of disease progression.
